CN114164142A - Lactobacillus plantarum Q16 with function of relieving nonalcoholic fatty liver caused by high-fat diet - Google Patents
Lactobacillus plantarum Q16 with function of relieving nonalcoholic fatty liver caused by high-fat diet Download PDFInfo
- Publication number
- CN114164142A CN114164142A CN202111313288.4A CN202111313288A CN114164142A CN 114164142 A CN114164142 A CN 114164142A CN 202111313288 A CN202111313288 A CN 202111313288A CN 114164142 A CN114164142 A CN 114164142A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- liver
- fat diet
- mice
- relieving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 76
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 76
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 76
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 20
- 235000009200 high fat diet Nutrition 0.000 title claims abstract description 13
- 210000004185 liver Anatomy 0.000 claims abstract description 57
- 230000000968 intestinal effect Effects 0.000 claims abstract description 23
- 230000037356 lipid metabolism Effects 0.000 claims abstract description 14
- 230000037149 energy metabolism Effects 0.000 claims abstract description 12
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 238000009825 accumulation Methods 0.000 abstract description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 9
- 239000006041 probiotic Substances 0.000 abstract description 7
- 235000018291 probiotics Nutrition 0.000 abstract description 7
- 230000000529 probiotic effect Effects 0.000 abstract description 3
- 238000013218 HFD mouse model Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 34
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 14
- 210000004379 membrane Anatomy 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 108010028554 LDL Cholesterol Proteins 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 108010023302 HDL Cholesterol Proteins 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 102000011690 Adiponectin Human genes 0.000 description 5
- 108010076365 Adiponectin Proteins 0.000 description 5
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 5
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 201000010063 epididymitis Diseases 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 4
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 4
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 4
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 4
- 108010018763 Biotin carboxylase Proteins 0.000 description 4
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 102000016267 Leptin Human genes 0.000 description 4
- 108010092277 Leptin Proteins 0.000 description 4
- 102000017946 PGC-1 Human genes 0.000 description 4
- 108700038399 PGC-1 Proteins 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 4
- 229940039781 leptin Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 3
- 101150073133 Cpt1a gene Proteins 0.000 description 3
- 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 description 3
- 241000589989 Helicobacter Species 0.000 description 3
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 3
- 101000927974 Homo sapiens Diacylglycerol O-acyltransferase 1 Proteins 0.000 description 3
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 3
- 241000192142 Proteobacteria Species 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- -1 ATGL Proteins 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 241001050506 Mucispirillum Species 0.000 description 2
- 241000160321 Parabacteroides Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 241000607493 Vibrionaceae Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229940100228 acetyl coenzyme a Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001147107 Chanos Species 0.000 description 1
- 241000222290 Cladosporium Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 description 1
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000588298 Homo sapiens Endoplasmic reticulum membrane sensor NFE2L1 Proteins 0.000 description 1
- 101000577547 Homo sapiens Nuclear respiratory factor 1 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 241001468155 Lactobacillaceae Species 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100028744 Nuclear respiratory factor 1 Human genes 0.000 description 1
- XOMRRQXKHMYMOC-UHFFFAOYSA-N O-palmitoylcarnitine Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-UHFFFAOYSA-N 0.000 description 1
- 241000192497 Oscillatoria Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003921 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Human genes 0.000 description 1
- 108090000310 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Proteins 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000017033 Porins Human genes 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 description 1
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides lactobacillus plantarum Q16 with the function of relieving nonalcoholic fatty liver caused by high-fat diet, which is classified and named as follows: lactobacillus plantarum (lactobacillus plantarum), deposited in the chinese type culture collection at 22 months 10/2021, address: wuhan, Wuhan university zip code: 430072, preservation number is CCTCCNO: M20211311. The strain can effectively reduce the weight of a high-fat diet mouse and the weight of the liver and fat, improve the lipid metabolism in the liver, inhibit the accumulation of triglyceride and improve the energy metabolism in the liver; in addition, the strain also has the capability of optimizing the structure of intestinal flora and has good probiotic function.
Description
One, the technical field
The invention relates to lactobacillus plantarum Q16 with a function of relieving non-alcoholic fatty liver disease caused by high-fat diet, belonging to the field of food microorganisms.
Second, background Art
In the past decades, the number of patients with non-alcoholic fatty liver disease has increased dramatically due to unreasonable dietary structure and lifestyle changes, and has become a serious public health problem worldwide. In addition, the occurrence of non-alcoholic fatty liver disease can induce other diseases such as liver cirrhosis, type ii diabetes, hypertension, cardiovascular diseases, etc., and thus, non-alcoholic fatty liver disease seriously harms human health. A large number of researches show that the occurrence of the non-alcoholic fatty liver disease is related to disorder of intestinal flora structures in a body, and specifically shows that the flora diversity, the symbiotic bacteria ratio and the conditioned pathogen number are reduced.
At present, dietary intervention aiming at the non-alcoholic fatty liver disease mainly comprises ingestion of prebiotics and probiotics, wherein the prebiotics comprise dietary fibers, polyphenols, oligosaccharides and the like, and the prebiotics and the probiotics can improve the intestinal flora structure, so that disorder of the micro-ecosystem is effectively inhibited. However, the mouthfeel of dietary fibers and oligosaccharides, and the absorption and processing techniques of polyphenols have restricted their development. With the growth of the fermentation industry in China, the variety and the number of products containing probiotics are increased, the probiotics can be colonized in human intestinal tracts, have the excellent characteristics of synthesizing essential vitamins, regulating the immune system, improving the intestinal flora structure, relieving the occurrence of metabolic diseases and the like, and are gradually valued and utilized by wide consumers. Therefore, screening of probiotics having the function of inhibiting lipid metabolism disorder is of great significance for development of functional foods.
Third, the invention
Technical problem
The invention aims to provide lactobacillus plantarum capable of relieving the function of nonalcoholic fatty liver caused by high-fat diet.
Technical scheme
The lactobacillus plantarum Q16 has the function of relieving nonalcoholic fatty liver caused by high-fat diet, and the strain Q16 is named in classification: lactobacillus plantarum (Lactobacillus plantarum), deposited in the chinese type culture collection at 22 months 10/2021, address: wuhan, Wuhan university zip code: 430072 with preservation number of CCTCC NO: M20211311.
The application of the lactobacillus plantarum Q16 refers to the application of the lactobacillus plantarum Q16 in relieving nonalcoholic fatty liver caused by high-fat diet. In particular to the application of lactobacillus plantarum Q16 in improving the lipid metabolism in the liver. Or the application of the lactobacillus plantarum Q16 in improving the energy metabolism in the liver. The application of the lactobacillus plantarum Q16 in improving the intestinal flora structure can also be referred to.
Has the advantages that:
(1) the lactobacillus plantarum Q16 provided by the invention obviously improves lipid metabolism and effectively relieves non-alcoholic fatty liver.
(2) The lactobacillus plantarum Q16 provided by the invention effectively improves energy metabolism in the liver and inhibits the accumulation of fat in the liver.
(3) The lactobacillus plantarum Q16 provided by the invention obviously optimizes the intestinal flora structure, thereby improving the intestinal microecosystem.
Animal experiments prove that the lactobacillus plantarum Q16 can effectively reduce the weight of obese mice and reduce the weight of epididymal adipose tissues and livers. Lactobacillus plantarum Q16 reduced mouse body weight, epididymal adipose tissue weight, and liver weight by approximately 14.52%, 26%, and 29.72%, respectively. Apparently, lactobacillus plantarum Q16 was able to inhibit the abnormal accumulation of fat in mice.
Animal experiments prove that the lactobacillus plantarum Q16 can improve lipid metabolism disorder in serum and liver. After the mice take the lactobacillus plantarum Q16, the content of triglyceride, the activity of ALT, the activity of AST and the content of leptin in serum are respectively reduced by 28.40%, 30.35%, 28.98% and 19.33%; the contents of HDL-C and adiponectin in serum are respectively increased by 19.11% and 56.63%; the content of triglyceride and LDL-C in the liver is respectively reduced by 23.60 percent and 20.28 percent; the content of glycerol and acetyl coenzyme A in the liver is respectively increased by 61.15 percent and 100.54 percent. Therefore, the lactobacillus plantarum Q16 can reduce the blood fat of the mice and inhibit the accumulation of fat in the livers of the mice.
Animal experiments prove that the lactobacillus plantarum Q16 promotes lipolysis and fatty acid oxidation in liver, and inhibits lipogenesis and fatty acid de novo synthesis. Western blot analysis results show that after Lactobacillus plantarum Q16 is ingested, the expression level of protein ATGL for regulating lipolysis in mouse liver is increased by about 173.28%; the expression level of protein CPT-1 alpha and PPAR-alpha for regulating fatty acid oxidation is increased by about 86.48% and 152.67%; the expression level of protein DGAT1 for regulating and controlling adipogenesis in the liver is down-regulated by about 20.86 percent; the expression levels of proteins FAS, ACC, SCD-1 and Srebp-1c which regulate the de novo synthesis of fatty acids were reduced by about 29.66%, 32.91%, 43.15% and 23.32%. These results fully demonstrate that lactobacillus plantarum Q16 is capable of directly regulating lipid metabolism-related proteins in the liver, thereby directly alleviating non-alcoholic fatty liver disease.
Animal experiments prove that the lactobacillus plantarum Q16 improves energy metabolism in the liver and promotes energy consumption. The result of Western blot analysis shows that the expression levels of PGC-1 alpha, p-AMPK alpha and FGF21 in mouse liver are respectively improved by 169.58%, 75.72% and 117.61% after the lactobacillus plantarum Q16 is ingested. Lactobacillus plantarum Q16 promotes energy expenditure, thereby indirectly inhibiting the accumulation of lipids in the liver.
Animal experiments prove that the lactobacillus plantarum Q16 can effectively increase the diversity of intestinal flora and the abundance of symbiotic bacteria, and simultaneously reduce the proportion of conditional pathogenic bacteria. Intestinal microbial sequencing results show that after lactobacillus plantarum Q16 is ingested, the relative abundance of conditional pathogenic bacteria proteobacteria, Desulfuromicrobiaceae, Desulfurvibrio, helicobacter and Mucispiralium in the colon of a mouse is respectively reduced by 72.67%, 83.12%, 84.88%, 85.34% and 81.88%; the symbiotic flora S24-7, the Lactobacillus family, the Lactobacillus and the Parabacteroides are respectively improved by 124.14%, 315.03%, 118.68% and 263.62%. These results indicate that lactobacillus plantarum Q16 inhibits the occurrence of intestinal inflammation, improves the intestinal micro-ecological environment, and then indirectly relieves non-alcoholic fatty liver by reducing the abundance of conditional pathogenic bacteria, promoting the proliferation of commensal flora.
Fourthly, explanation of the attached drawings:
FIG. 1 is a phylogenetic tree of Lactobacillus plantarum Q16;
FIG. 2 shows the body weight, liver weight and epididymal adipose tissue weight of each group of mice;
FIG. 3 is a graph showing the serum levels of triglycerides, leptin, adiponectin, total cholesterol, glutamic-pyruvic transaminase, glutamic-oxaloacetic transaminase, high density lipoprotein cholesterol, low density lipoprotein cholesterol, tumor lethal factor-alpha, and interleukin-1 beta in each group of mice;
FIG. 4 shows the amounts of triglyceride, total cholesterol, HDL cholesterol, LDL cholesterol, glycerol and acetyl-CoA in the livers of various groups of mice;
FIG. 5 is a photograph of H & E and oil red stained sections of livers of various groups of mice;
FIG. 6 shows the expression levels of proteins involved in lipid metabolism in the livers of mice in each group;
FIG. 7 shows the expression levels of energy metabolism-related proteins in the livers of mice in each group;
FIG. 8 is an analysis of the diversity of the flora Alpha in the colon of each group of mice;
FIG. 9 is an analysis of the intestinal flora at the phylum level in each group of mice;
FIG. 10 is an analysis of intestinal flora at the family level for each group of mice;
FIG. 11 is an analysis of the intestinal flora at the genus level in each group of mice.
Biological preservation
Lactobacillus plantarum Q16, the strain being classified under the name: lactobacillus plantarum (Lactobacillus plantarum), deposited in the chinese type culture collection at 22 months 10/2021, address: wuhan, Wuhan university zip code: 430072, preservation number is CCTCC NO: M20211311.
Fifth, detailed description of the invention
The invention is further illustrated by specific embodiments and with reference to the accompanying drawings:
1. identification and culture of lactobacillus plantarum Q16
Transporting the yoghourt self-made by Qinghai herdsmen to a laboratory at low temperature, mixing the yoghourt sample with the sterile MRS according to the volume ratio of 1:100 under the aseptic condition, and enriching the lactic acid bacteria. Uniformly coating the cultured flora in an MRS solid culture medium, picking a single colony for culturing again, carrying out streak culture on the cultured bacteria, picking the single colony again, continuing to expand and cultivate, repeating the steps for 3 times, picking the single colony, and carrying out sequencing identification. A single colony was identified as Lactobacillus plantarum, which we named Lactobacillus plantarum Q16 (FIG. 1).
2. Preparation of Lactobacillus plantarum Q16 bacterial suspension
The cultured Lactobacillus plantarum Q16 was centrifuged (8000 rpm, 10 minutes), the supernatant was discarded, washed three times with 0.1mol/L sterilized PBS buffer (pH 7.2), and the concentration of Lactobacillus plantarum Q16 was adjusted to 10 using this buffer9cfu/mL。
3. Effect of Lactobacillus plantarum Q16 on mouse body weight and organs
Animal experiments 4-week-old mice of a specific pathogen-free grade (purchased from the university of Yangzhou, comparative medicine center) were used, and after one week of acclimation, normal group (NC group) mice were fed with normal diet, and model group (HFD group) and sample group (PL group) mice were fed with high-fat diet. According to the method of Dang et al (Dang et al, Food funct.,2018,9, 3630-3639), the mice in the sample group were gavaged 10 days9Lactobacillus plantarum Q16 of cfu, both normal and model groupsThe mice were gavaged with an equal volume of sterile normal saline for 8 weeks, the weight of the mice was recorded, and the weight of the liver and epididymal fat was measured, all measurements being in eight replicates. As shown in FIG. 2, after the Lactobacillus plantarum Q16 was ingested, the body weight of the mice was reduced from 50.88 + -2.88 g to 43.50 + -3.46 g, the liver weight was reduced from 2.32 + -0.41 g to 1.63 + -0.17 g, and the epididymis adipose tissue weight was reduced from 1.55 + -0.37 g to 1.15 + -0.25 g, compared to the high fat model group.
4. Effect of Lactobacillus plantarum Q16 on parameters related to lipid metabolism in mouse serum
The method of Zhu et al (Zhu et al, Food funct.,2018,9, 3509-. The kit is used for measuring the content of triglyceride, leptin, adiponectin, glutamic pyruvic transaminase (ALT), glutamic oxaloacetic transaminase (AST), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) in serum (all the kits are purchased from Nanjing BioLimited), and the results are shown in figure 3. compared with the mice of a high-fat model group, after the Lactobacillus plantarum Q16 is ingested, the concentration of triglyceride in the serum of the mice is reduced to 6.96 +/-1.41 mmol/L, the ALT activity is reduced to 14.63 +/-2.17U/L from 21.01 +/-4.19U/L, the AST activity is reduced to 55.89 +/-3.22U/L from 78.69 +/-10.75U/L, the concentration of HDL-C is reduced to 3.96 +/-0.53 mmol/L from 3.20 +/-0.57 mmol/L, and the leptin concentration is reduced to 3.96 +/-0.53 mmol/L from 3.89 ng/0.53 ng/L, the concentration of the adiponectin rises from 8.57 +/-2.02 mg/L to 19.76 +/-4.58 mg/L. The concentrations of total cholesterol and LDL-C in serum did not change significantly. Therefore, lactobacillus plantarum Q16 was effective in improving lipid metabolism in serum of mice with a high fat diet.
5. Effect of Lactobacillus plantarum Q16 on parameters related to lipid metabolism in mouse liver
According to the method of Gao et al (Gao et al, Food funct.,2021,12, 373-386), after the liver of the mouse is removed, 100mg of liver sample is accurately weighed into a sterile centrifuge tube, 1ml of sterile PBS buffer (0.1mol/L, pH 7.2) is added, homogenized by an automatic homogenizer until no obvious block is formed, then centrifuged at 4 ℃ and 2000 rpm for 10 minutes, and the supernatant is sucked into another sterile centrifuge tube and stored at 4 ℃ for later use. The levels of triglyceride, HDL-C, LDL-C, total cholesterol, glycerol, and acetyl-CoA in the liver homogenate supernatant were measured using a kit, and the protein content in the liver homogenate supernatant was measured using BCA (kit available from Shanghai Biyunnan Bio Inc.) for calibration of parameters. As shown in FIG. 4, after the intake of Lactobacillus plantarum Q16, the triglyceride concentration in the liver of mice decreased from 22.12. + -. 3.65mmol/mg prot to 16.90. + -. 3.42mmol/mg prot, the LDL-C concentration decreased from 4.28. + -. 0.55mmol/mg prot to 3.41. + -. 0.55mmol/mg prot, the glycerol concentration increased from 32.57. + -. 10.53mmol/mg prot to 52.48. + -. 5.07mmol/mg prot, the acetyl-CoA concentration increased from 1.02. + -. 0.44pmol/μ g prot to 2.04. + -. 0.25pmol/μ g prot, and the total cholesterol and HDL-C concentration in the liver did not change significantly, compared with the mice in the high fat model group. Therefore, the lactobacillus plantarum Q16 can obviously reduce the content of triglyceride and LDL-C in the liver, increase the content of glycerol and acetyl coenzyme A and effectively inhibit the accumulation of fat in the liver.
6. Effect of Lactobacillus plantarum Q16 on mouse liver architecture
Referring to Wang et al (Wang et al, j. funct. foods,2020,68,103923), 400 mg of fresh mouse liver was accurately weighed, washed with sterile saline and placed in a sterile centrifuge tube, 1ml of 4% paraformaldehyde was added for tissue fixation, and stored at 4 degrees for later use. Then, all tissues were dehydrated, embedded in paraffin, sectioned with a microtome, stained with hematoxylin, eosin, and oil red, respectively, and the microstructure of the tissues was observed with a microscope.
As shown in FIG. 5, the liver of the mouse in the high-fat model group had a large number of lipid droplets, and the results of oil red staining showed that the liver had a large amount of lipids; in contrast, mice administered lactobacillus plantarum Q16 showed no significant lipid droplet cells in the liver and a significant reduction in lipids.
7. Effect of Lactobacillus plantarum Q16 on lipid metabolism in the liver of mice
In order to explore the lipid metabolism regulation mechanism of lactobacillus plantarum Q16, the invention measures the expression level of some proteins related to lipid metabolism.
Referring to Xia et al (Xia et al, biomed. Pharmacother.,2019,118,109287), 100mg of liver sample was accurately weighed, placed in 1ml of a lysate (containing protease and phosphatase inhibitors) of Shanghai Biyun Bio Inc., and three small magnetic beads, the tissue sample was thoroughly disrupted by a homogenizer, centrifuged at 12000g for 20min at 4 ℃ to obtain the supernatant as total protein of the tissue, the supernatant was taken into another centrifuge tube, and the protein concentration was determined by a BCA kit (purchased from Shanghai Biyun Bio Inc.). 6-15% of separation gel and concentrated gel are prepared, and proper separation gel concentration is selected according to the molecular weight of the target protein. Mixing protein extract and protein sample buffer solution, heating in 100 deg.C boiling water for 8min, centrifuging at 10000g for 1min, adding the mixture into protein gel pore groove (ensuring total amount of each pore protein to be 50 μ g), adding rainbow Marker (purchased from Nanjing Nuojingzhan biological Co., Ltd.) into each gel via a hole, running at 90V constant pressure for 30min, separating strips on the rainbow Marker, changing to 120V constant pressure, and running to the bottom of separation gel from the Marker. The protein gel was removed, the gel near the target protein was cut with a scalpel, the protein was transferred with an NC membrane (available from GE Healthcare Life Science, USA), and the membrane was placed in a buffer for membrane transfer and then transferred at a constant current of 400mA for 20min (the target protein is less than 150 kDa). Then the NC membrane was placed in a blocking solution (TBST + 5% skimmed milk powder) and blocked for 2 hours, after blocking, the NC membrane was placed in a diluted primary antibody solution (CPT-1. alpha., PPAR. alpha., Srebp-1c, ACC, SCD-1, ATGL, DGAT1 and FGF21 primary antibodies were obtained from Affinity Biosciences, Inc., in Heizhou, FAS primary antibodies were obtained from Cell Signaling Technology, Inc., in U.S.A.; GAPDH, PGC-1. alpha., SIRT1, p-AMPK. alpha., AMPK. and NRF1 primary antibodies were obtained from Shanghai Biyun Biosciences, Inc.) and the NC membrane was fully contacted with the antibody by ice-bath for 12 hours on a decolorization shaker. After incubation, the unbound antibody on the membrane was washed with membrane washing solution (TBST + 1% skim milk powder) three times for 8min each, and then the NC membrane was incubated with diluted secondary antibody (purchased from Strobilekusho bioengineering, Inc. of Wuhan Dynasty) at room temperature for 2h, and then washed with membrane washing solution three times for 8min each. ECL luminescence solution (available from Affinity Biosciences, Inc., Chang.) was dropped on the membrane by a pipette, the membrane was gently shaken to bring the luminescence solution into sufficient contact with the membrane surface, exposure was taken in an ECL chemiluminescence apparatus, and the optical density of the band was quantitatively analyzed by Image J software.
As shown in FIG. 6, the expression levels of Fatty Acid Synthase (FAS), acetyl-CoA carboxylase (ACC), stearoyl-CoA desaturase-1 (SCD-1), sterol regulatory element-binding protein-1 c (Srebp-1c), and diacylglycerol-acyltransferase 1(DGAT1) in the liver of mice were decreased by 0.39, 0.43, 0.60, 0.40, and 0.36 fold, respectively, after the intake of Lactobacillus plantarum Q16, as compared to the mice in the high-fat model group; the expression levels of carnitine palmitate transferase-1 alpha (CPT-1 alpha), peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and fatty triglyceride lipase (ATGL) in the liver are respectively improved by 0.36, 0.51 and 0.70 times, and the results fully indicate that the lactobacillus plantarum Q16 can directly regulate the protein related to lipid metabolism in the liver so as to relieve the nonalcoholic fatty liver.
8. Effect of Lactobacillus plantarum Q16 on energy metabolism-related proteins in mouse liver
In order to explore the mechanism of the lactobacillus plantarum Q16 for regulating energy metabolism, the invention measures the expression level of some proteins related to energy metabolism.
And 7, determining the energy metabolism related protein in the liver by using the conditions of extracting the protein and Western blot in the liver.
As shown in fig. 7, the expression levels of peroxisome proliferator-activated receptor- γ coactivator-1 α (PGC-1 α), phosphorylated AMP-dependent protein kinase α (p-AMPK α), and fibroblast growth factor 21(FGF21) in the liver of the mouse were increased by 0.79, 0.62, and 0.62 times, respectively, as compared to the mice in the high fat model group, after ingestion of lactobacillus plantarum Q16. The lactobacillus plantarum Q16 is shown to indirectly inhibit the accumulation of lipid in the liver by activating FGF21/Adiponectin/AMPK alpha/PGC-1 alpha pathway, thereby enhancing the mitochondrial biosynthesis, improving the energy metabolism in the liver and promoting the energy consumption.
9. Regulation of intestinal flora structure by lactobacillus plantarum Q16
In order to explore the influence of lactobacillus plantarum Q16 on the structure of intestinal flora, the structure of intestinal flora in the colon of a mouse is determined by taking colon contents as a research object and utilizing a metagenomic sequencing technology.
Referring to the method of Li et al (Li et al, Food Res. int.,2021,143,110270), 200mg of mouse feces were quickly weighed into a sterilized 2mL centrifuge tube, crushed, homogenized, placed on ice, and feces genomic DNA extraction kit (from Biochemical technology, Inc., Beijing Tiangen) was performed as follows: adding 1.4mL of buffer GSL into a fecal sample, shaking for 1min, uniformly mixing the sample, incubating for 10min at 70 ℃, vortexing for 15s, centrifuging for 1min at 12000 Xg, transferring supernatant into a new sterilized centrifuge tube, adding an inhibitor adsorption sheet into the centrifuge tube, shaking until the adsorption sheet is completely dissolved, standing for 1min at room temperature, centrifuging for 3min at 12000 Xg, sucking supernatant into a new centrifuge tube, centrifuging for 3min at 12000 Xg, sucking 200 mu L of supernatant into another centrifuge tube, adding 15 mu L of protease K, adding 200 mu L of buffer GB, vortexing for 15s at shaking, incubating for 10min at 70 ℃, adding 200 mu L of absolute ethyl alcohol, vortexing and uniformly mixing, adding mixed solution into an adsorption column, collecting by using a sleeve, purifying DNA by using buffer GD and rinsing solution PW respectively, collecting DNA by using buffer TB, and storing in a refrigerator at-20 ℃. The purity and concentration of DNA were measured by Nanodrop as to OD260/OD280 and concentration, and the ratio of OD to OD of about 1.8 indicated that the purity of DNA was good. Then amplifying the V3-V4 region of the 16S rRNA of the bacteria by adopting primers of a forward primer 338F (5'-ACTCCTACGGGAGGCAGCA-3') and a reverse primer 806R (5 '-GGACTACHVGGGTWTCTAAT-3'), wherein the PCR reaction system is as follows: mu.L of each of 1. mu.L of LDNA template, 0.25. mu. L Q5 DNA polymerase, 5 Xreaction buffer and 5 Xhigh GC buffer, 1. mu.L of 10. mu.M forward and reverse primers, 0.5. mu.L of 10mM dNTP, 11.25. mu.L of ddH2And O. The PCR reaction conditions are as follows: pre-denaturation at 98 ℃ for 30s, 25 cycles of denaturation at 98 ℃ for 15s, annealing at 56 ℃ for 30s and elongation at 72 ℃ for 30s, and mostThen renaturation is carried out for 5min at 72 ℃, and the amplified product is purified and sequenced. Because the number of sequences obtained by high-throughput sequencing is huge, original data needs to be filtered and screened to remove chimera sequences, so that the accuracy of the data can be improved, the working efficiency is improved, in addition, for the convenience of subsequent analysis, the sequences also need to be clustered, and clustering with the sequence similarity of more than or equal to 97 percent is usually carried out, namely a classification Unit (OTU) can be operated. On the basis of OTU division, Alpha diversity analysis can be further carried out to determine the abundance of communities in the sample, the composition of the flora in the sample can be further determined through different taxonomic levels, and Beta diversity analysis can explain the difference of the flora among sample groups.
The overall structure of intestinal flora of each group is shown in figure 8, and compared with mice in a high-fat model group, lactobacillus plantarum Q16 improves the Chano 1 index, Shannon index and Simpson index by about 0.57 times, 0.08 times and 0.01 times respectively, which shows that lactobacillus plantarum Q16 improves the richness and diversity of intestinal flora of the mice.
In addition, differences in flora at the phylum, family and genus level were also evident. As shown in fig. 9-11, lactobacillus plantarum Q16 inhibited the proliferation of harmful flora, such as proteobacteria, vibrionaceae, rikenaceae, oscillatoria, cladosporium, devulcanium, helicobacter, allorhabdus and Mucispirillum, at phylum, family and genus level, as compared to mice of the high-fat model group; and significantly increases the abundance of the probiotic groups bacteroidetes, S24-7, lactobacillaceae, lactobacillus and parabacteroides. On one hand, proteobacteria, vibrionaceae, vibrio, helicobacter and Mucispirillum are the main conditional pathogens for causing intestinal inflammation, and the pathogens cause the translocation of lipid and endotoxin in the intestinal tract into a circulating system by causing the intestinal inflammation and further damaging the intestinal barrier so as to cause the systemic inflammation and the accumulation of the lipid; on the other hand, S24-7, Lactobacillus and Parabacteroids can reduce the pH value in the intestinal tract by producing organic acid, improve the intestinal tract micro-ecosystem and effectively enhance the intestinal tract barrier, and in addition, short chain fatty acid produced by the bacteria can enter the liver through enterohepatic circulation, so that the activity of AMPK is improved, the generation of fatty acid oxidation reaction in the liver is promoted, and the abnormal accumulation of lipid in the liver is inhibited.
In conclusion, the lactobacillus plantarum Q16 relieves the non-alcoholic fatty liver caused by high-fat diet through three ways of regulating the protein of lipid metabolism, the protein of energy metabolism and the intestinal flora structure, and has good probiotic effect.
Sequence listing
<110> Nanjing university of agriculture
<120> Lactobacillus plantarum Q16 having function of alleviating non-alcoholic fatty liver disease caused by high-fat diet
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
actcctacgg gaggcagca 19
<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Claims (6)
1. Lactobacillus plantarum Q16 having the function of relieving nonalcoholic fatty liver caused by high-fat diet, the strain Q16 is named after classification: lactobacillus plantarum (lactobacillus plantarum), deposited in the chinese type culture collection at 22 months 10/2021, address: wuhan, Wuhan university zip code: 430072 with preservation number of CCTCC NO: M20211311.
2. The use of lactobacillus plantarum Q16, according to claim 1.
3. The use of claim 2, wherein the Lactobacillus plantarum Q16 is used for relieving non-alcoholic fatty liver disease caused by high-fat diet.
4. The use according to claim 2 or 3, which is the use of Lactobacillus plantarum Q16 for improving lipid metabolism in the liver.
5. The use according to claim 2 or 3, which is the use of Lactobacillus plantarum Q16 for improving energy metabolism in the liver.
6. The use according to claim 2 or 3, wherein the Lactobacillus plantarum Q16 is used for improving the intestinal flora structure.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111313288.4A CN114164142A (en) | 2021-11-08 | 2021-11-08 | Lactobacillus plantarum Q16 with function of relieving nonalcoholic fatty liver caused by high-fat diet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111313288.4A CN114164142A (en) | 2021-11-08 | 2021-11-08 | Lactobacillus plantarum Q16 with function of relieving nonalcoholic fatty liver caused by high-fat diet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114164142A true CN114164142A (en) | 2022-03-11 |
Family
ID=80478178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111313288.4A Pending CN114164142A (en) | 2021-11-08 | 2021-11-08 | Lactobacillus plantarum Q16 with function of relieving nonalcoholic fatty liver caused by high-fat diet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114164142A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115089619A (en) * | 2022-07-18 | 2022-09-23 | 南昌大学 | Application of lactobacillus plantarum ZDY2013 in preparation with function of relieving non-alcoholic fatty liver disease |
| CN117618477A (en) * | 2023-11-29 | 2024-03-01 | 广西爱生生命科技有限公司 | Application of lactobacillus plantarum strain A21094 in preparation of products for preventing and/or treating non-alcoholic fatty liver disease |
| CN118542886A (en) * | 2024-07-30 | 2024-08-27 | 杭州菌吾细研生物科技有限公司 | Application of lactobacillus plantarum MLL-6, composition and compound microbial preparation |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111467506A (en) * | 2020-03-10 | 2020-07-31 | 河北师范大学 | Application of lactobacillus plantarum powder in regulating fat rat lipid metabolism and intestinal flora |
| CN111909869A (en) * | 2020-07-23 | 2020-11-10 | 大连工业大学 | Lactobacillus plantarum Y44 and application thereof in preparation of medicines or health-care products for relieving obesity or resisting hyperlipidemia |
| CN112813003A (en) * | 2021-02-08 | 2021-05-18 | 青岛海华莱康生物医药技术有限公司 | Lactobacillus plantarum and application thereof in preparation of medicine or food for relieving diseases caused by hyperlipidemia |
| WO2021194040A1 (en) * | 2020-03-24 | 2021-09-30 | (주)메디톡스 | Microorganism for improving liver function or inhibiting fat accumulation, and uses of same |
| WO2021215627A1 (en) * | 2020-04-21 | 2021-10-28 | (주)에이투젠 | Composition for preventing or treating lipid-related metabolic diseases, comprising lactobacillus plantarum atg-k2 or atg-k6 |
-
2021
- 2021-11-08 CN CN202111313288.4A patent/CN114164142A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111467506A (en) * | 2020-03-10 | 2020-07-31 | 河北师范大学 | Application of lactobacillus plantarum powder in regulating fat rat lipid metabolism and intestinal flora |
| WO2021194040A1 (en) * | 2020-03-24 | 2021-09-30 | (주)메디톡스 | Microorganism for improving liver function or inhibiting fat accumulation, and uses of same |
| WO2021215627A1 (en) * | 2020-04-21 | 2021-10-28 | (주)에이투젠 | Composition for preventing or treating lipid-related metabolic diseases, comprising lactobacillus plantarum atg-k2 or atg-k6 |
| CN111909869A (en) * | 2020-07-23 | 2020-11-10 | 大连工业大学 | Lactobacillus plantarum Y44 and application thereof in preparation of medicines or health-care products for relieving obesity or resisting hyperlipidemia |
| CN112813003A (en) * | 2021-02-08 | 2021-05-18 | 青岛海华莱康生物医药技术有限公司 | Lactobacillus plantarum and application thereof in preparation of medicine or food for relieving diseases caused by hyperlipidemia |
Non-Patent Citations (1)
| Title |
|---|
| 陆婧婧: "植物乳杆菌调节抑制高脂诱导小鼠肥胖的形成" * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115089619A (en) * | 2022-07-18 | 2022-09-23 | 南昌大学 | Application of lactobacillus plantarum ZDY2013 in preparation with function of relieving non-alcoholic fatty liver disease |
| CN117618477A (en) * | 2023-11-29 | 2024-03-01 | 广西爱生生命科技有限公司 | Application of lactobacillus plantarum strain A21094 in preparation of products for preventing and/or treating non-alcoholic fatty liver disease |
| CN118542886A (en) * | 2024-07-30 | 2024-08-27 | 杭州菌吾细研生物科技有限公司 | Application of lactobacillus plantarum MLL-6, composition and compound microbial preparation |
| CN118542886B (en) * | 2024-07-30 | 2024-10-29 | 杭州菌吾细研生物科技有限公司 | Application of lactobacillus plantarum MLL-6, composition and compound microbial preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114507621B (en) | Lactobacillus plantarum and application thereof in reducing uric acid, weight and inflammation | |
| CN114164142A (en) | Lactobacillus plantarum Q16 with function of relieving nonalcoholic fatty liver caused by high-fat diet | |
| Zhao et al. | Eucommia ulmoides leaf extract alters gut microbiota composition, enhances short‐chain fatty acids production, and ameliorates osteoporosis in the senescence‐accelerated mouse P6 (SAMP6) model | |
| CN113498433B (en) | Composition for preventing, improving or treating obesity or fatty liver disease comprising leuconostoc citrate WiKim0104 | |
| CN111437294B (en) | Lactic acid bacteria formula for preventing acute and chronic alcoholic liver injury and application thereof | |
| Qian et al. | Effects of lactobacillus casei YBJ02 on lipid metabolism in hyperlipidemic mice | |
| CN115697361A (en) | Composition for preventing and treating lipid-related metabolic diseases comprising lactobacillus plantarum ATG-K2 or lactobacillus plantarum ATG-K6 | |
| CN115216422B (en) | Lactobacillus rhamnosus and application thereof | |
| JP7266110B2 (en) | Composition for prevention, improvement or treatment of obesity or fatty liver disease containing Weissella hellenica WIKIM0103 | |
| CN116286551B (en) | Application of bifidobacterium longum subspecies infantis in regulating in-vivo fat metabolism, shaping, reducing fat and improving obesity | |
| CN109593678B (en) | Bifidobacterium longum YH295 and application thereof in preparing product for reducing abdominal obesity risk | |
| CN111304119A (en) | Feeding bacillus subtilis for degrading fumonisins and application thereof | |
| Li et al. | Effects of two strains of Lactobacillus isolated from the feces of calves after fecal microbiota transplantation on growth performance, immune capacity, and intestinal barrier function of weaned calves | |
| CN111164201B (en) | Lactobacillus paracasei GKS6 for improving metabolic syndrome, use thereof, pharmaceutical composition and edible composition | |
| Okyere et al. | Bacillus toyonensis SAU-19 and SAU-20 isolated from Ageratina adenophora alleviates the intestinal structure and integrity damage associated with gut dysbiosis in mice fed high fat diet | |
| CN116064286B (en) | Lactobacillus helveticus ZJUIDS11 for improving nonalcoholic liver disease and application thereof | |
| CN115992059B (en) | Lactobacillus johnsonii for producing feruloyl esterase and application thereof in relieving ulcerative colitis | |
| CN113797232B (en) | Composition with insulin resistance relieving function and application thereof | |
| Yamada et al. | Lactic Acid Bacteria Isolated from Japanese Fermented Fish (Funa‐Sushi) Inhibit Mesangial Proliferative Glomerulonephritis by Alcohol Intake with Stress | |
| CN114437968B (en) | Lactobacillus acidophilus NX2-6 with obesity relieving function and application thereof | |
| Dong et al. | Optimizing the scale-up production of fermented astragalus and its benefits to the performance and egg quality of laying hens | |
| CN117866798A (en) | Lactobacillus fermentum GLF-217 and its use in ulcerative colitis, hyperlipidemia and reduction of organ damage | |
| CN105143438B (en) | Lactobacillus bacterium | |
| CN117701469A (en) | Lactobacillus paracasei IMAUJBC1 capable of efficiently reducing cholesterol and application thereof | |
| Helmy et al. | Does Torulaspora delbrueckii has some probiotic capabilities? In vitro and in vivo assessment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220311 |